KRAS and neoplasm: However, conflicting data persist in three domains: (1) Dose Optimization Paradox: While pharmacokinetic modeling correlates ≥ 15 mM plasma VC with kirsten rat sarcoma viral oncogene (KRAS)-mutant tumor regression, lower doses (5–10 mM) paradoxically enhance glutathione synthesis in 32% of glioblastoma cases (20, 21).